ACCEPTUSE OF COOKIES: To give you the best possible experience, this website uses cookies.
By continuing to use our website you are giving your consent to cookies being used. Cookies Policy
At Sagetis Biotech we are devoted to developing innovative drug delivery technologies to tackle challenging unmet medical needs.
Based in Barcelona, Sagetis Biotech was founded in 2010 as a spin-off from GEMAT (Materials Engineering Group) at IQS.
Sagetis Biotech aims to provide solutions to major bottlenecks found in pharmaceutical companies when developing products in different therapeutic areas.
The company's versatile, polymeric-based platforms
are designed to tackle highly challenging areas, such as:
  • Delivery through difficult-to-cross barriers
    (e.g blood-brain barrier, intestinal mucus gel layer, ocular)
  • Efficient transfection of genetic material, using both
    viral and non-viral vectors
  • Bone and cartilage enhanced regeneration.
Technology Platforms
  • NanoBBB: designed to take drugs (including small molecules, peptides and proteins) across the blood brain barrier via surface-modified biodegradable nanoparticles.
  • NanoGene: designed to offer efficient transfection of genetic material encapsulated in nanoparticles containing plasmids, siRNA or mRNA.
Latest Corporate Presentation
Eduard Diviu, BD and Eng.
CEO, CFO, Co-founder and Chairman of the Board at Sagetis Biotech.
With a marked entrepreneurial profile and a hands-on, science driven approach with a global view, Eduard has played a key role in the successful rise of capital of the company since its foundation. He is involved in the negotiations with Pharma companies and establishment of IP strategies. Skilful in management, human resources and setting up and executing strategic plans, he has also been appointed to participate in different entrepreneurial programmes such as Ignite Fast Track (Cambridge Judge Business School, University of Cambridge) and MassConnect to promote the biotech industry in Massachusetts and the Catalan Bioregion.
Salvador Borrós, PhD.
CSO, Co-founder and member of the Board at Sagetis Biotech. Full Professor at IQS. PhD in Chemical Engineering. Scientific Leader of Material Engineering Group (GEMAT). Member of the IQS's Bioengineering Department.
Vast and proven experience, amongst others, in Materials Science (Chemistry and Chemical Engineering), Materials Science Fundamentals (Industrial Engineering), Materials Technology (Industrial Engineering), Materials Selection, Polymeric and Ceramics Materials, Biomaterials and Medical Devices (where he also holds a Master in Bioengineering).
Noteworthy, he has robust knowledge and experience in Biomaterials (Stimuli sensitive polymeric nanoparticles for drug delivery; Design of biomimetic surfaces with both chemical and mechanical signalling) and Smart surfaces (Design and rapid manufacturing fabrication of scaffolds for bone and cartilage regeneration). Salvador has over 90 publications and 10 patents. He is in charge of the research activities carried out at Sagetis.
Xavier Rivero, BSc
COO and partner at Sagetis Biotech. Bachelor's degree in Pharmacy. Extensive knowledge of Pharmaceutical Industry, in particular in the R&D area, with special focus in Pharmaceutics.
Driven by passion for differentiated, innovative products that cover unmet needs. Xavier has more than 25 years of experience in the Pharmaceutical industry in R&D and is in charge of the Development activities carried out by the company in coordination with CROs. He has designed the Development activities that have been key for obtaining Venture Capital for the company. Xavier has been also a key figure to assess the potential risks and solutions to transform Sagetis technologies into feasible products.
Anna Cascante, PhD
Head of Molecular and Cellular Biology at Sagetis Biotech.
Dr. Cascante got her PhD in Biochemistry and Molecular Biology from the University of Barcelona at the Center for Genomic Regulation (CRG) in Barcelona, where she developed gene therapy strategies for pancreatic cancer. In 2006, she moved to Stockholm where she worked as a post-doctoral fellow in the Department of Neuroscience at Karolinska Institutet studying the epigenetic regulation of Neural Stem Cell differentiation during development. Afterwards, Anna moved to the Vall d'Hebron Institut of Oncology (VHIO) where she further studied the role of epigenetics related to tumour progression, in particular Glioblastoma Multiforme. With an extensive experience in biomedical research, she joined Sagetis Biotech to lead the Molecular and Cellular Biology activities in 2011.
Vladimir Torchilin, PhD
Vladimir P Torchilin is a University Distinguished Professor and Director at the Center for Pharmaceutical Biotechnology and Nanomedicine at the School of Pharmacy, Northeastern University (MA, USA).
Vladimir Torchilin graduated from the Moscow University with an MS in Chemistry and also obtained his PhD and DSc in Polymer Chemistry, Chemical Kinetics and Catalysis, and Chemistry of Physiologically Active Compounds in 1971 and 1980, respectively. In 1991 Dr. Torchilin joined Massachusetts General Hospital and Harvard Medical School as the Head of Chemistry Program, Center for Imaging and Pharmaceutical Research, and Associate Professor of Radiology. Since 1998 Dr. Torchilin is with Northeastern University. He was the Chair of the Department of Pharmaceutical Sciences 1998-2007. His research interests have focused on biomedical polymers, polymeric drugs, immobilized medicinal enzymes, drug delivery and targeting, pharmaceutical nanocarriers for diagnostic and therapeutic agents, and experimental cancer immunology. He has published more than 300 original papers, more than 100 reviews and book chapters, wrote and edited 10 books, including Immobilized Enzymes in Mecicine, The Handbook on Targeted Delivery of Imaging Agents, Liposomes: A Practical Approach, Nanoparticulates as Pharmaceutical Carriers, Multifunctional Pharmaceutical Nanocarriers, Biomedical Aspects of Drug Targeting, Delivery of Protein and Peptide Drugs in Cancer, and holds more that 40 patents. He is Editor-in-Chief of Current Drug Discovery Technologies, Co-Editor-in-Chief of Drug Delivery and on the Editorial Boards of many leading journals in the field including Journal of Controlled Release (Review Editor), Bioconjugate Chemistry, Advanced Drug Delivery Reviews, European Journal of Pharmaceutics and Biopharmaceutics, Journal of Drug Targeting, Molecular Pharmaceutics, Journal of Biomedical Nanotechnology, and few others. Among his many awards, Professor Torchilin was the recipient of the 1982 Lenin Prize in Science and Technology (the highest scientific award in the former USSR). He was elected as a Member of European Academy of Sciences. He is also a Fellow of American Institute of Medical and Biological Engineering and of American Association of Pharmaceutical Scientists (AAPS), and received the 2005 Research Achievements in Pharmaceutics and Drug Delivery Award from the AAPS and 2007 Research Achievements Award from the Pharmaceutical Sciences World Congress. In 2005-2006 he served as a President of the Controlled Release Society.

Robert Elfont, MD, PhD
Robert Elfont is a Johns Hopkins-trained neurologist with subspecialty training in neuroimmunology and neurovirology.
He possesses over ten years in the pharmaceutical and biotechnology industry and eight years in academic practice. Dr. Elfont is knowledgeable in all phases of clinical development and he has an extensive expertise in CNS drug development, including neurologic, psychiatric, and pain indications. He has experience with both small molecules and biologics.

Xavier Luria, MD
He has extensive experience in international drug development, in particular clinical, and is a specialist in pharmaceutical medicine.
He has been exposed to this area from a triangle perspective: as a hospital’s medical doctor with postgraduate training in internal medicine, as clinical researcher and management and leadership positions in pharma industry and, finally, as relevant European Medicines Agency (EMA) manager.
He has been extensively involved setting up strategy, design and operations of drug development programs and post-marketing drug surveillance, as well as on portfolio management and in-and-out licensing opportunities.
His competence in drug regulation has been developed through more than 18 years of experience in the pharmaceutical industry dealing with several worldwide regulatory authorities and further 6 years in a regulatory key position at the EMA.
Caixa Capital Risc
VC firm of "la Caixa" that invests in early stage Spanish companies led by committed teams that have the potential for high growth.
Red de Inversores Privados y Family Offices
Investor’s Network made up of executives, business leaders, family offices, and other people and organizations with entrepreneurial drive that are interested in investing in new companies or businesses with the potential for growth. 4 members of this Network have invested in Sagetis Biotech.
CDTI. Iniciativa NEOTEC
The Centre for Industrial Technological Development (CDTI) is a Public Business Entity, answering to the Ministry of Economy and Competitiveness, which fosters the technological development and innovation of Spanish companies.
CDTI is supporting Sagetis Biotech through different instruments: NEOTEC, INNTERNACIONALIZA and PID.
Empresa Nacional de Innovación S.A. (ENISA)
ENISA aims to provide small and medium enterprises with financial instruments and long term funding formulas enabling them to strengthen their financial structures.
Seventh Framework Programme (EU)
The Seventh Framework Programme (FP7) bundles all research-related EU initiatives together under a common roof playing a crucial role in reaching the goals and growth, competitiveness and employment; along with a new Competitiveness and Innovation Framework Programme (CIP), Education and Training programmes, and Structural and Cohesion Funds for regional convergence and competitiveness.
Sagetis Biotech is currently participating in two FP7 projects: ALEXANDER and RESTORATION.
Ministerio de Economía y Competitividad (MINECO)
Sagetis Biotech has been granted funding from the following instruments: INNPACTO 2012, Subprograma INNCORPORA FPGS, INNCORPORA TORRES QUEVEDO AND RETOS COLABORACIÓN 2014.